NCT02041325View on ClinicalTrials.gov

Investigation of the Enhancement of Response to Hepatitis B Vaccine by Lenalidomide in Plasma Cell Dyscrasias

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

January 31, 2011

Study Completion Date

April 30, 2014

Conditions
Plasma Cell Disorder
Interventions
DRUG

Lenalidomide

Subjects will receive oral CC-5013 (lenalidomide) at 25 mg qd for 7 days prior to and 7 days after the vaccine.

DRUG

Placebo

Subjects will receive placebo for 7 days prior to and 7 days after the vaccine.

Trial Locations (2)

02130

VA Boston Healthcare System, Boston

02215

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Dana-Farber Cancer Institute

OTHER

lead

Boston VA Research Institute, Inc.

OTHER

NCT02041325 - Investigation of the Enhancement of Response to Hepatitis B Vaccine by Lenalidomide in Plasma Cell Dyscrasias | Biotech Hunter | Biotech Hunter